Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
“Enriched and emboldened after successful fights against asbestos and tobacco companies, some of the nation's top plaintiffs' lawyers have trained their sights on drug makers, claiming that many giant pharmaceutical companies have hidden the dangers of medicines the lawyers say have harmed thousands of people.” Thus began an article on the front page of the May 18, 2003 the Sunday New York Times, entitled, “Trial Lawyers Are Now Focusing on Lawsuits Against Drug Makers,” which reported on a significant increase in the number of lawsuits against pharmaceutical companies over the last several years. (See Alex Berenson, “Trial Lawyers Are Now Focusing on Lawsuits Against Drug Makers,” N.Y. Times, May 18, 2003, at 1.) In fact, during the last 3 years alone, ten of the 19 products liability litigations transferred to the Judicial Panel on Multidistrict Litigation have involved pharmaceuticals or medical devices. (See Web site of the Judicial Panel on Multidistrict Litigation at www.jpml.uscourts.gov.)
In order to avoid drowning in the sea of mass tort litigation, drug and medical device companies must aggressively and “offensively” defend these actions — and do so as soon as the mass tort litigation emerges. Critical to stemming the mass tort tide is an understanding of the factors that drive the filing of these actions against pharmaceutical and medical device companies: 1) the ease with which controversial issues relating to drugs and medical devices can be recognized; and 2) complicated causation issues. Armed with that understanding, the single most important pre-trial goal for any defendant must be the early exposure of frivolous claims based on tenuous causation and junk science. Of course, the immediate benefit of this strategy is obvious: the dismissal of the individual case at hand. The benefits of early exposure, however, are much more far-reaching in that it can act as a deterrent to the filing of new cases, as well as a catalyst for the dismissal of existing actions based on similar unsupported theories. Early exposure of frivolous claims is the key to stopping the growth of a particular mass tort litigation, as well as to causing its ultimate demise.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
A federal district court in Miami, FL, has ruled that former National Basketball Association star Shaquille O'Neal will have to face a lawsuit over his promotion of unregistered securities in the form of cryptocurrency tokens and that he was a "seller" of these unregistered securities.
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
Blockchain domain names offer decentralized alternatives to traditional DNS-based domain names, promising enhanced security, privacy and censorship resistance. However, these benefits come with significant challenges, particularly for brand owners seeking to protect their trademarks in these new digital spaces.
In recent years, there has been a growing number of dry cleaners claiming to be "organic," "green," or "eco-friendly." While that may be true with respect to some, many dry cleaners continue to use a cleaning method involving the use of a solvent called perchloroethylene, commonly known as perc. And, there seems to be an increasing number of lawsuits stemming from environmental problems associated with historic dry cleaning operations utilizing this chemical.